Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
CNY 4.77
(0.0%)
CNY 4.77
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.73 Billion CNY | 12.2% |
| 2022 | 6 Billion CNY | -2.45% |
| 2021 | 6.15 Billion CNY | 4.09% |
| 2020 | 5.9 Billion CNY | -12.7% |
| 2019 | 6.76 Billion CNY | -0.27% |
| 2018 | 6.78 Billion CNY | 28.2% |
| 2017 | 5.29 Billion CNY | -12.07% |
| 2016 | 6.02 Billion CNY | 13.55% |
| 2015 | 5.3 Billion CNY | 48.03% |
| 2014 | 3.58 Billion CNY | 22.48% |
| 2013 | 2.92 Billion CNY | 6.97% |
| 2012 | 2.73 Billion CNY | 28.78% |
| 2011 | 2.12 Billion CNY | 17.97% |
| 2010 | 1.79 Billion CNY | 27.93% |
| 2009 | 1.4 Billion CNY | 28.46% |
| 2008 | 1.09 Billion CNY | -11.53% |
| 2007 | 1.23 Billion CNY | 49.12% |
| 2006 | 829.91 Million CNY | -4.21% |
| 2005 | 866.4 Million CNY | 43.66% |
| 2004 | 603.09 Million CNY | 28.65% |
| 2003 | 468.79 Million CNY | 6.35% |
| 2002 | 440.8 Million CNY | 13.98% |
| 2001 | 386.74 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.6 Billion CNY | -11.82% |
| 2024 Q1 | 1.82 Billion CNY | 17.8% |
| 2024 Q3 | 1.46 Billion CNY | -8.96% |
| 2023 Q3 | 1.41 Billion CNY | -13.11% |
| 2023 Q4 | 1.54 Billion CNY | 9.07% |
| 2023 Q1 | 2.13 Billion CNY | 40.89% |
| 2023 FY | 6.73 Billion CNY | 12.2% |
| 2023 Q2 | 1.63 Billion CNY | -23.31% |
| 2022 Q1 | 1.59 Billion CNY | 4.22% |
| 2022 FY | 6 Billion CNY | -2.45% |
| 2022 Q2 | 1.25 Billion CNY | -21.54% |
| 2022 Q3 | 1.64 Billion CNY | 31.25% |
| 2022 Q4 | 1.51 Billion CNY | -7.92% |
| 2021 Q1 | 1.59 Billion CNY | 16.43% |
| 2021 Q3 | 1.5 Billion CNY | -1.79% |
| 2021 Q4 | 1.53 Billion CNY | 1.93% |
| 2021 FY | 6.15 Billion CNY | 4.09% |
| 2021 Q2 | 1.52 Billion CNY | -3.93% |
| 2020 Q4 | 1.36 Billion CNY | 1.42% |
| 2020 FY | 5.9 Billion CNY | -12.7% |
| 2020 Q3 | 1.34 Billion CNY | -11.14% |
| 2020 Q2 | 1.51 Billion CNY | -9.67% |
| 2020 Q1 | 1.67 Billion CNY | 22.06% |
| 2019 Q2 | 1.96 Billion CNY | 16.18% |
| 2019 Q3 | 1.74 Billion CNY | -11.13% |
| 2019 Q1 | 1.68 Billion CNY | 21.25% |
| 2019 FY | 6.76 Billion CNY | -0.27% |
| 2019 Q4 | 1.37 Billion CNY | -21.11% |
| 2018 Q2 | 1.79 Billion CNY | 0.67% |
| 2018 FY | 6.78 Billion CNY | 28.2% |
| 2018 Q4 | 1.39 Billion CNY | -23.4% |
| 2018 Q1 | 1.78 Billion CNY | 17.99% |
| 2018 Q3 | 1.81 Billion CNY | 1.32% |
| 2017 FY | 5.29 Billion CNY | -12.07% |
| 2017 Q4 | 1.51 Billion CNY | 4.67% |
| 2017 Q3 | 1.44 Billion CNY | 16.05% |
| 2017 Q2 | 1.24 Billion CNY | 13.39% |
| 2017 Q1 | 1.09 Billion CNY | -26.04% |
| 2016 Q3 | 1.48 Billion CNY | -5.42% |
| 2016 FY | 6.02 Billion CNY | 13.55% |
| 2016 Q4 | 1.48 Billion CNY | -0.31% |
| 2016 Q2 | 1.57 Billion CNY | 6.47% |
| 2016 Q1 | 1.47 Billion CNY | -4.95% |
| 2015 Q2 | 1.31 Billion CNY | 46.58% |
| 2015 FY | 5.3 Billion CNY | 48.03% |
| 2015 Q1 | 896.82 Million CNY | -11.18% |
| 2015 Q4 | 1.55 Billion CNY | 1.15% |
| 2015 Q3 | 1.53 Billion CNY | 16.88% |
| 2014 Q2 | 946.79 Million CNY | 29.23% |
| 2014 Q3 | 892.43 Million CNY | -5.74% |
| 2014 Q4 | 1 Billion CNY | 13.15% |
| 2014 FY | 3.58 Billion CNY | 22.48% |
| 2014 Q1 | 732.62 Million CNY | -11.34% |
| 2013 Q4 | 826.38 Million CNY | 16.94% |
| 2013 Q2 | 719.82 Million CNY | 7.23% |
| 2013 Q1 | 671.29 Million CNY | -21.41% |
| 2013 FY | 2.92 Billion CNY | 6.97% |
| 2013 Q3 | 706.65 Million CNY | -1.83% |
| 2012 FY | 2.73 Billion CNY | 28.78% |
| 2012 Q1 | 610.48 Million CNY | 7.36% |
| 2012 Q4 | 854.18 Million CNY | 30.19% |
| 2012 Q3 | 656.09 Million CNY | 7.05% |
| 2012 Q2 | 612.91 Million CNY | 0.4% |
| 2011 Q3 | 517.97 Million CNY | 12.43% |
| 2011 Q2 | 460.72 Million CNY | -6.35% |
| 2011 Q1 | 491.97 Million CNY | 0.36% |
| 2011 FY | 2.12 Billion CNY | 17.97% |
| 2011 Q4 | 568.61 Million CNY | 9.78% |
| 2010 Q2 | 440.35 Million CNY | 0.48% |
| 2010 Q1 | 438.26 Million CNY | -2.07% |
| 2010 FY | 1.79 Billion CNY | 27.93% |
| 2010 Q4 | 490.23 Million CNY | 13.86% |
| 2010 Q3 | 430.56 Million CNY | -2.22% |
| 2009 Q3 | 391.07 Million CNY | 42.87% |
| 2009 Q2 | 273.72 Million CNY | -6.97% |
| 2009 Q1 | 294.22 Million CNY | -2.04% |
| 2009 FY | 1.4 Billion CNY | 28.46% |
| 2009 Q4 | 447.52 Million CNY | 14.43% |
| 2008 Q3 | 225.08 Million CNY | -16.45% |
| 2008 Q4 | 300.34 Million CNY | 33.44% |
| 2008 FY | 1.09 Billion CNY | -11.53% |
| 2008 Q1 | 300.1 Million CNY | -7.39% |
| 2008 Q2 | 269.38 Million CNY | -10.23% |
| 2007 Q2 | 212.39 Million CNY | 1.08% |
| 2007 Q1 | 210.11 Million CNY | -20.78% |
| 2007 FY | 1.23 Billion CNY | 49.12% |
| 2007 Q3 | 295.86 Million CNY | 39.3% |
| 2007 Q4 | 324.03 Million CNY | 9.52% |
| 2006 Q1 | 201.73 Million CNY | -21.88% |
| 2006 Q2 | 148.86 Million CNY | -26.21% |
| 2006 Q3 | 214.1 Million CNY | 43.83% |
| 2006 Q4 | 265.21 Million CNY | 23.87% |
| 2006 FY | 829.91 Million CNY | -4.21% |
| 2005 Q1 | 182.28 Million CNY | 4.16% |
| 2005 Q4 | 258.22 Million CNY | 20.47% |
| 2005 Q3 | 214.34 Million CNY | 1.32% |
| 2005 FY | 866.4 Million CNY | 43.66% |
| 2005 Q2 | 211.54 Million CNY | 16.05% |
| 2004 FY | 603.09 Million CNY | 28.65% |
| 2004 Q1 | 132.54 Million CNY | 2.33% |
| 2004 Q2 | 132.3 Million CNY | -0.18% |
| 2004 Q3 | 163.22 Million CNY | 23.37% |
| 2004 Q4 | 175.01 Million CNY | 7.22% |
| 2003 Q4 | 129.52 Million CNY | -0.49% |
| 2003 Q3 | 130.16 Million CNY | 0.0% |
| 2003 FY | 468.79 Million CNY | 6.35% |
| 2002 FY | 440.8 Million CNY | 13.98% |
| 2001 FY | 386.74 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | 22.81 Billion CNY | 70.496% |
| Zhangzhou Pientzehuang Pharmaceutical., Ltd | 10.05 Billion CNY | 33.064% |
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. | 2.31 Billion CNY | -191.227% |
| Aurora Optoelectronics Co.,Ltd. | 327.9 Million CNY | -1953.255% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | 121.77 Million CNY | -5428.722% |
| NanJing Pharmaceutical Company Limited | 53.58 Billion CNY | 87.436% |
| GuangYuYuan Chinese Herbal Medicine Co., Ltd. | 1.28 Billion CNY | -424.355% |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | 3.07 Billion CNY | -118.923% |